Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration
mBio · 31.10.2023 · 14 (5)
DOI: 10.1128/mbio.01295-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 31.10.2023. Verfasst von Rick Heida und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen , Groningen, The Netherlan…. Hauptthemen laut MEDLINE: Vaccines, Virus Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF).
Abstract (Originalsprache)
Many of the current pandemic threats are caused by viruses that infect the respiratory tract. Remarkably though, the majority of vaccines and antiviral drugs are administered via alternative routes. In this perspective, we argue that the pulmonary route of administration deserves more attention in the search for novel therapeutic strategies against respiratory virus infections. Firstly, vaccines administered at the viral portal of entry can induce a broader immune response, employing the mucosal arm of the immune system; secondly, direct administration of antiviral drugs at the target site leads to superior bioavailability, enabling lower dosing and reducing the chance of side effects. We further elaborate on why the pulmonary route may induce a superior effect compared to the intranasal route of administration and provide reasons why dry powder formulations for inhalation have significant advantages over standard liquid formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen , Groningen, The Netherlands.
ORCID-Profile: Rick Heida
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)
Zitieren
APA
Heida, R., Frijlink, H. W., & Hinrichs, W. L. J. (2023). Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration. mBio, 14(5). https://doi.org/10.1128/mbio.01295-23
Vancouver
Heida R, Frijlink HW, Hinrichs WLJ. Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration. mBio. 2023;14(5). doi:10.1128/mbio.01295-23
BibTeX
@article{Heida2023,
author = {Heida, Rick and Frijlink, Henderik W and Hinrichs, Wouter L J},
title = {Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration},
journal = {mBio},
year = {2023},
volume = {14},
number = {5},
doi = {10.1128/mbio.01295-23}
}
EUVIMED